Shots:
- Gustave Roussy to receive funding and support from Daiichi Sankyo for integrative research program including clinical, translational, and preclinical studies for DS-1062 and patritumab deruxtecan in lung and breast cancer respectively
- The research program includes two P-II studies evaluating the efficacy, safety, and markers of response and resistance to DS-1062 & patritumab deruxtecan in patients with advanced NSCLC, progressed on anti-PD-1/PD-L1 therapy and Pt-doublet CT & HER3 expressing mBC respectively
- Each study will enroll ~100 patients and will be conducted at several sites in France. The 1EPs of the studies will be ORR and 2EPs includes clinical benefit rate, PFS, DoR, OS, and safety measures. DS-1062 is a TROP2 directed DXd ADC while patritumab deruxtecan is a HER3 directed DXd ADC
Click here to read full press release/ article | Ref: Daiichi Sankyo| Image: ETHealthworld
